Tigecycline for the treatment of infections due to resistant Gram-positive organisms

Bibliography

• CARON C: MRSA and MRSE: is there an answer? Clin. Microbiol. Infect. (2000) 6(Suppl. 2):17-22.
   PubMed Web of Science ®Google Scholar
• KELLNER JD: Drug-resistant Streptococcus pneumoniae infections: clinical importance, drug treatment and prevention. Semin. Resp. Infect. (2001) 16:186-195.
   PubMedGoogle Scholar
• POOTOOLAL J, NEU J, WRIGHT GD: Glycopeptide antibiotic resistance. Ann. Rev. Pharmacol. Toxicol. (2002) 42:381-408.
   PubMed Web of Science ®Google Scholar
• EDMOND M: Glycopeptide-resistant Staphylococcus aureus. Int. J. Clin. Prac. (2000) 115:66-71.
   Google Scholar
• DIEKMA DJ, JONES RN: Oxazolidinone antibiotics. Lancet (2001) 358:1975-1982.
   Google Scholar
• ALLINGTON DR, RIVEY MP: Quinupristin/dalfopristin: a therapeutic review. Clin. Ther. (2001) 23:24-44.
   PubMed Web of Science ®Google Scholar
• GUAY DRP: Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy (2004) 24(1):58-68.
   PubMed Web of Science ®Google Scholar
• MALABARBA A, CIABATTI R: Glycopeptide derivatives. Curr. Med. Chem. (2001) 8:1759-1773.
   PubMed Web of Science ®Google Scholar
• GIAMARELLOU H, O’RIORDAN W, HARRIS H, OWEN S, PORTER S, LOUTIT J: Phase III trial comparing 3 – 7 days of oritavancin versus 10 – 14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSI). Program And Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (September 14 – 17 2003) (L-739a).
   Google Scholar
• MERCIER R-C, HREBICKOVA L: Oritavancin: a new avenue for resistant Gram-positive bacteria. Exp. Rev. Anti-infective Ther. (2005) 3(3):325-332.
   PubMedGoogle Scholar
• STRYJEWSKI ME: Telavancin (TLV) versus standard therapy (ST) for treatment of complicated Gram-positive skin and soft tissue infections (cSSTI). Infectious Disease Society of America 41st Annual Meeting, San Diego, USA (October 3 2004) (Abstract 517).
   Google Scholar
• VICURON PHARMACEUTICALS: New drug application submitted for dalbavancin to US Food and Drug Administration: once-weekly antibiotic designed to treat growing problem of hospital Staphylococcal infections (Press Release).
   Google Scholar
• SUM P-E, PETERSEN P: Synthesis and structure–activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. (1999) 9(10):1459-1462.
   PubMed Web of Science ®Google Scholar
• CHOPRA I, ROBERTS, M: Tetracycline antibiotics: Mode of action, applications, molecular biology, and antibacterial resistance. Microbiol. Mol. Biol. Revs (2001) 65:232-256.
   PubMed Web of Science ®Google Scholar
• PETERSEN PJ, JACOBUS NV, WEISS WJ, SUM PE, TESTA RT: In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycyclamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. (1999) 43(4):783-744.
   Web of Science ®Google Scholar
• BETRIU C, CULEBRAS E, GÓMEZ M, RODRÍGUEZ-AVIAL I, PICAZO JJ: In vitro activity of tigecycline against Bacteroides species. J. Antimicrob. Chemother. (2005) 56:349-352.
   Google Scholar
• POSTIER RG, GREEN SL, KLEIN SR, ELLIS-CROSSE EJ, LOH E, TIGECYCLINE STUDY GROUP: Results of a multicenter, randomized, open-label efficacy study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin. Ther. (2004) 26(5):704-714.
   PubMed Web of Science ®Google Scholar
• MURALIDHARAN G, GETSY J, MAYER P et al.: Pharmacokinetics (PK), safety, and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. Abstracts of the Interscience Conference on Antimicrobial Agents in Chemotherapy, San Francisco, California, USA (September 27 – 30 1999):39.
   Google Scholar
• MURALIDHARAN G, MOJAVERIAN P, MICALIZZI M et al.: The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents in Chemotherapy, Toronto, Ontario, Canada (September 17 – 20 2000) (Abstract A-502).
   Google Scholar
• TROY SM, MURALIDHARAN G, MICALIZZI M, MOJAVERIAN P, SALACINSKI L, RAIBLE D: The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents in Chemotherapy, Chicago, Illinois, USA (September 14 – 17 2003) (Abstract A-22).
   Google Scholar
• NANNINI EC, PAI SR, SINGH KV, MURRAY BE: Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob. Agents Chemother. (2003) 47(2):529-532.
   PubMed Web of Science ®Google Scholar
• SESOKO S, UMEMURA K, NAKASHIMA M: Pharmacokinetics (PK), safety and tolerability of tigecycline (GAR-936) in healthy Japanese males. Abstracts of the Interscience Conference on Antimicrobial Agents in Chemotherapy, San Diego, California, USA (September 27 – 30 2002) (Abstract A-1403).
   Google Scholar
• MURRAY J, WILSON S, KLEIN S, YELLIN A, LOH E: The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase II clinical trial. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents in Chemotherapy, Washington, DC, USA (2003) (Abstract L-739).
   Google Scholar
• PROJAN SJ: Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy (2000) 20(9):219S-223S.
   PubMed Web of Science ®Google Scholar
• MILATOVIC D, SCHMITZ F, VERHOEF J, FLUIT A: Activities of the glycylcycline tigecycline (GAR-936) against 1.924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. (2003) 47(1):400-404.
   PubMed Web of Science ®Google Scholar
• WALLACE R, BROWN-ELLIOTT B, CRIST C, MANN L, WILSON R: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. (2002) 46(10):3164-3167.
   PubMed Web of Science ®Google Scholar
• EDELSTEIN P, WEISS W, EDELSTEIN M: Activities of tigecycline (GAR-936) against Legionella pneumophilia in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. (2003) 47(2):533-540.
   PubMed Web of Science ®Google Scholar
• JACOBUS N, McDERMOTT L, RUTHAZER R, SNYDMAN D: In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. (2004) 48(3):1034-1036.
   PubMed Web of Science ®Google Scholar
• CHOPRA I: Glycylcylines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. (2001) 1(5):464-469.
   PubMedGoogle Scholar
• ZHANEL GG, HOMENUIK K, NICHOL K et al.: The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 64(1):63-88.
   PubMed Web of Science ®Google Scholar
• BRADFORD PA, WEAVER-SANDS DT, PETERSEN PJ: In vitro activity of tigecycline against isolates from patietns enrolled in Phase III clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. (2005) 41:S315-S332.
   PubMed Web of Science ®Google Scholar
• DARTOIS N: Results of a Phase III, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infections. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents in Chemotherapy, Washington DC, USA (2004) (Session 97; Control 3841; Presentation L-986).
   Google Scholar
• DARTOIS N, GIOUD-PAQUET M, ELLIS-GROSSE EJ et al.: Tigecycline versus imipenem/cilastatin for treatment of complicated intra-abdominal infections. 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents in Chemotherapy, Washington, DC, USA (2004) (Session 97; Control 3841; Presentation L-992c).
   Google Scholar
• ROSE G, LOH E: Efficacy and safety of tigecycline compared with vancomycin/aztreonam in patients with complicated skin and skin structure infections: Results from a Phase III, randomized, double-blind trial. 11th International Symposium on Staphylococci and Staphylococcal Infections, Charleston, USA (October 24 – 27 2004) (Presentation TH-13).
   Google Scholar
• ELLIS-GROSSE EJ, LOH E on behalf of tigecycline 301 study group: Tigecycline compared with imipenem/cilastatin in the treatment of complicated intra-abdominal infections. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (April 2 – 5 2005).
   Google Scholar
• FOMIN P, BEURAN M, GRADAUSKAS A et al. on behalf of the 306 Study Group: Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int. J. Surgery (2005) 3:35-47.
   PubMedGoogle Scholar
• SACCHIDANAND, PENN S, EMBIL RL et al. for the Tigecycline Study 300 Trial Group: Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase III, randomized, double-blind trial. Int. J. Infect. Dis. (2005) 9(5):251-261.
   PubMed Web of Science ®Google Scholar
• OLIVA ME, REKHA A, YELLIN A et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect. Dis. (2005) 5:88.
   PubMed Web of Science ®Google Scholar
• BREEDT J, TERAS J, GARDOVSKIS J et al.: The safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind Phase III comparison study with vancomycin/aztreonam. Antimicrob. Agents Chemother. (2005) 49(11):4658-4666.
   PubMed Web of Science ®Google Scholar